Bruker (NASDAQ:BRKR) Stock Price Breaks Above 50-Day Moving Average – Here’s What Happened

Bruker Corporation (NASDAQ:BRKR) crossed above its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $58.95 and traded as high as $68.98. Bruker shares last traded at $63.79, with a volume of 7,408,425 shares.

Bruker News Roundup

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Bruker reported Q3 adjusted earnings of $0.56 per share, versus the $0.42 consensus estimate, and revenue of $874 million, above the $865 million estimate. Revenue grew 1.6% year over year. Bruker Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Management highlighted margin expansion, strong bookings, and a return of U.S. academic demand. The company also sees potential for double-digit EPS growth in fiscal 2027, supporting optimism about future performance. Bruker sees US academic demand return in Q3, targets double-digit EPS growth in FY27
• Neutral Sentiment: Bruker forecast 2026 revenue of $3.52 billion–$3.56 billion, with non-GAAP EPS of $2.10–$2.15. The EPS range brackets the $2.12 analyst estimate, while the revenue midpoint is slightly below the $3.56 billion consensus. Bruker 2026 revenue outlook
• Negative Sentiment: Coverage also flagged a substantial goodwill charge, which could weigh on reported results and temper the positive read-through from stronger margins and adjusted earnings. Bruker Q3 2026: Margin Surge Masks a Steep Goodwill Charge

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Zacks Research cut shares of Bruker from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 2nd. Barclays raised their target price on shares of Bruker from $58.00 to $70.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. UBS Group began coverage on shares of Bruker in a report on Wednesday, September 9th. They issued a “neutral” rating and a $65.00 target price on the stock. Leerink Partners lifted their target price on shares of Bruker from $60.00 to $80.00 and gave the company an “outperform” rating in a report on Tuesday, September 29th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Bruker in a research note on Monday, August 31st. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $59.43.

Bruker Stock Up 12.9%

The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.92 and a current ratio of 1.85. The firm has a fifty day moving average price of $58.95 and a 200 day moving average price of $50.48. The firm has a market capitalization of $9.72 billion, a price-to-earnings ratio of -91.13, a PEG ratio of 1.73 and a beta of 1.26.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Wednesday, November 4th. The medical research company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.42 by $0.14. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%. The firm had revenue of $874.00 million for the quarter, compared to the consensus estimate of $865.16 million. During the same period in the previous year, the business earned $0.45 earnings per share. The company’s revenue for the quarter was up 1.6% compared to the same quarter last year. As a group, sell-side analysts expect that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st were issued a $0.05 dividend. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Bruker’s dividend payout ratio (DPR) is -28.57%.

Insider Buying and Selling

In other Bruker news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total transaction of $105,740.00. Following the sale, the vice president directly owned 134,806 shares in the company, valued at approximately $7,127,193.22. The trade was a 1.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 27.20% of the company’s stock.

Hedge Funds Weigh In On Bruker

Institutional investors and hedge funds have recently made changes to their positions in the stock. Global Retirement Partners LLC acquired a new stake in shares of Bruker in the second quarter valued at about $38,000. Provenance Wealth Advisors LLC purchased a new stake in Bruker during the third quarter worth about $52,000. Root Financial Partners LLC purchased a new stake in Bruker during the third quarter worth about $57,000. Essential Partners LLC acquired a new position in Bruker during the first quarter worth about $36,000. Finally, FNY Investment Advisers LLC acquired a new position in Bruker during the second quarter worth about $60,000. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.